Two drugs used together controlled a teen's pituitary tumor
Original title: Case Report: Neurosurgery, octreotide, cabergoline, radiotherapy, pasireotide and pegvisomant - a multimodal strategy for adolescent acrogigantism.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
These drugs are already used in people, but this is just one patient's story, not a trial.
The short version
One teenager's hard-to-treat pituitary tumor was finally brought under control by two drugs given together.
What was studied. Doctors reported on one teenage girl with a pituitary tumor that made too much growth hormone. They described each treatment she was given over time.
What they found. The tumor was found at age 13 years and 10 months, while doctors looked into her long-lasting headaches. A scan showed a tumor 38 x 23 x 32 mm that had grown into nearby tissue. Surgery, proton beam radiation, and several drugs one at a time did not get her hormone levels down. Two drugs given together, pegvisomant and octreotide LAR, brought her hormone level back to normal, and her tumor stayed stable on scans.
What this means, and what it doesn't
What it could mean: When one drug alone does not control growth hormone, a mix of two drugs may work. Care like this needs a team of doctors and long follow-up.
What it doesn't mean: This is one patient's story, not a study in a group of people. A single case cannot show how well a treatment works for others. It is not a cure, and it does not change what doctors offer most patients today. Any plan like this would be decided by your own care team.
Source: PubMed, October 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.